Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Stem Cells: A New Approach to Treating Cancer

This article was originally published in Start Up

Executive Summary

Cancer stem cells are a hot, promising new approach to treating cancer--one which may not only prevent cancer from spreading, but also help diagnose and even cure the disease. Start-ups are beginning to emerge, and so is investor interest.

You may also be interested in...



Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.

Taking Aim At Recurrence: Targeting Cancer Stem Cells To Stop Proliferation

An emerging field of oncology drug development offers the potential for eradicating all remaining cancer cells following treatment – and thus preventing recurrence – by targeting the so-called cancer stem cells that are thought to be involved in cancer proliferation, treatment resistance, and metastasis.

Start-Up Quarterly Statistics, Q4 2008

Highlights from the Q4 2008 review of start-up dealmaking: Fundraising in the biopharma, med-device, and in vitro diagnostics industries totaled $551 million, a 41% decrease from 3Q and just another indication of the tough economic times. Of the three acquisitions done this quarter--two in biopharma and one in devices--only one had a disclosed value. About one-third of the 19 biopharma alliances were in the cancer therapy area.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel